LSU Health NEW ORLEANS
Institutional Biosafety Committee

LSU HSC-New Orleans Institutional Biosafety Committee
Meeting Minutes

Date: Wednesday, June 11, 2025
Time: 1:00 PM- 2:25 PM
Location: Zoom

Members present:
1. Zea, *IBC Chair*
2. Catling, *IBC Vice Chair*
3. Didier Mejia, *BSO*
4. Aiyar
5. Boulares
6. Wang
7. Yue
8. Zabaleta
9. Curran, *Local Non-affiliated Member*
10. Guidry, *Local Non-affiliated Member*

Members excused:
1. Birke, *Animal Containment*

Other Individuals in Attendance:
1. Landry, *IBC/IACUC Coordinator*
2. Fuselier, *IBC/IACUC Specialist*
3. Stewart, *IRB Analyst I*
4. Stormer, *IRB Analyst II*

1:01pm **Quorum Present**
The IBC has 11 voting members and 6 are required to conduct business

1:02pm **Call to Order**
The IBC Chair called the meeting to order

1:03pm **Conflicts of Interest**
The IBC Chair reminded all members present to identify any conflicts of interest as each application is reviewed.

1:05pm **Review and approval of previous meeting minutes**

- May 14, 2025
  A motion was made and seconded to approve the minutes as written. Motion carried.
- June 3, 2025 (Ad Hoc)
  A motion was made and seconded to approve the minutes as written. Motion carried.
  These minutes were posted on the ORS IBC webpage.

1:11pm **Review of Prior Business**

- Review of NIH Transparency Memo and Minutes Template

Committee members were reminded of the new NIH guidelines requiring increased transparency. As part of compliance, this meeting and future minutes will be posted on the ORS IBC webpage.

1:12pm **New Business**

- The Committee reviewed recent changes to the IBC website, available at: https://www.lsuhsc.edu/administration/academic/ors/ibc/au_meeting_dates.aspx
- New Committee Member
  The Committee is currently seeking a new member. Candidate nominations will be reviewed at the July meeting, and a vote on the final candidate will take place at that time.

1:16pm **Review of Incidents & Non-compliance**

- **Administrative Closures Due to Inactivity from May 14, 2025 to June 11, 2025**

Title	Number	PI Name	Submission Type	Status	Continuing Review Date	Expiration Date
A Randomized, Phase II Trial of circulating Tumor DNA guided 2nd Line Adjuvant Therapy for High Residual Risk, Stage II-III, estrogen Receptor Positive, HER2 Negative Breast Cancer (DARE)	2547	Loch, Michelle	Renewed/Amended	Closed	April 22, 2025	April 22, 2026

- **Protocols that are suspended, in "Grace Period" and destined for administrative closure:**

Title	Number	PI Name	Submission Type	Status	Continuing Review Date	Expiration Date
The role of antiretroviral therapy in susceptibility to oral human papillomavirus (HPV) infection	7010	Cameron, Jennifer	Initial	Approved	June 05, 2025	June 05, 2029

- **Inspections/Ongoing Oversight**
  There were no updates or issues to report from EH&S at this time.

1:18pm **IBC Registrations & Amendments for Review**

- **Applications and amendments determined by the Chair or IBC Coordinator that do not fall under the NIH Guidelines for FCR**
  - **New Protocols**

IBC #8651	Long-Term Effects of Adolescent Alcohol on Pain
PI Name	Gilpin, Nicholas
Project Overview	This project investigates the long-term effects of adolescent alcohol exposure on pain-related brain circuits, specifically the central amygdala (CeA) projections to the ventrolateral periaqueductal gray (VIPAG). Using a rat model, researchers will examine how intermittent adolescent alcohol exposure influences pain sensitivity in adulthood, particularly after an inflammatory pain challenge. The study will also explore the role of corticotropin-releasing factor receptor 1 in modulating these effects. Findings aim to clarify the link between early

	alcohol use and chronic pain, a critical issue affecting millions who self-medicate with alcohol. No recombinant viral vectors or pathogens requiring containment beyond standard ABSL-1 practices will be used. All work will be conducted under BSL-1 conditions in accordance with LSUHSC safety protocols.
NIH Guidelines Section(s)	III-E-3
Risk Assessment & Discussion	Personnel working in the laboratory will use appropriate personal protective equipment (PPE), including gloves, lab coats or disposable gowns, and surgical masks. Vapor chambers are connected to a passive exhaust that ensures constant alcohol removal to decrease the exposure risks for personnel.
Training	All institutional trainings required are complete for lab staff listed in the registration: • COI in Research • Laboratory Safety • IBC Compliance • BBP High Risk
EH&S Assessment	The lab was inspected, and no deficiencies were found.
Occupational Health Representative review (if applicable)	N/A
Biosafety Level Assignment	BSL-1 ABSL-1
IACUC status (if applicable)	Application approved
IBC Vote	The IBC Chair determined that the application met all necessary requirements and was approved through designated member review (DMR). FCR was not required.

- **Amendments and Renewals**

Title	Number	PI Name	Submission Type	Expiration Date	Amendment Description
Propagation of Glioblastoma cells in immunodeficient and syngeneic mouse models	4351	Reiss, Krzysztof	Amended	March 30, 2027	Change in Personnel
Alcohol and rmTBI effects on the blood-brain barrier and dementia	7477	Vita, Sydney	Amended	June 19, 2029	Change in personnel
Development of protective vaccine and antibody as	5011	Xin, Hong	Amended	January 31, 2028	Update of location of lab Room number.

Immunotherapies for Disseminated Candidiasis and MDR infections					
Mechanisms of Prohealing Lipid Autocrines/paracrines of Macrophages and Nerves in Diabetic Wound Re-innervation	7167	Hong, Song	Amended	April 27, 2029	Addition of reagent—no change in BSL.
The effects of chronic alcohol use and aging on cardiovascular function	8486	Paloczi, Janos	Amended	April 17, 2030	Changes in personnel
Alcohol-induced injury to Heart	5414	Paloczi, Janos	Amended	June 06, 2028	The addition of a new anesthetic
Alcohol and traumatic brain injury: neuronal and behavioral consequences	5023	Molina, Patricia	Amended	February 17, 2028	Change in personnel
Cholinergic contribution to hippocampal information processing	7416	Gasparini, Sonia	Renewed	June 14, 2029	
Preclinical investigation of a novel onclytic virus in the treatment of pancreatic cancer	5154	Moaven, Omeed	Renewed	June 21, 2028	
Cyclic AMP (cAMP), Arginase (ARG) and Nitric Oxide (NO) in the Pathogenesis of Tuberculosis (TB), and Non-Tuberculous Mycobacteria (NTM)	7282	Zea, Arnold	Renewed	May 24, 2029	

Women and Their Children's Health Study	2532	Peters, Edward	Renewed	June 24, 2026	
MICRORNA (MIRNA) SIGNALING IN ALZHEIMER'S DISEASE(AD)	5434	Bazan, Nicolas	Renewed	July 11, 2028	
Cannabinoid regulation of SIV-mediated tissue injury	7600	Molina, Patricia	Renewed	July 17, 2029	
Molecular regulation of skeletal muscle function in children with cerebral palsy implication for therapeutic targets	7587	Simon Peter, Liz	Renewed	July 16, 2029	
Docosanoids modulate homeostasis and cell survival after ischemic stroke	4471	Bazan, Nicolas	Renewed/Amended	July 01, 2027	Change in personnel
Epstein-Barr virus: a co-conspirator with human papillomavirus in anogenital dysplasia	4500	Cameron, Jennifer	Renewed/Amended	June 24, 2027	Change in personnel
Triage tests for people with HPV	7263	Cameron, Jennifer	Renewed/Amended	June 02, 2029	Change in personnel
CARC Analytical Core	4450	Siggins, Robert	Renewed/Amended	June 15, 2027	Change in personnel

- **Applications reviewed and Suspended (in Grace Period) by the Chair after modifications requested by FCR. Continuing IBC oversight is required with annual reviews.**

  N/A

- **Full Committee Review of applications subject to *NIH Guidelines and our Policies*. Continuing IBC oversight required.**

IBC #6978	**Molecular mechanisms underlying alcohol consumption and reward**
PI Name	Maiya, Rajani

Project Overview	Alcohol Use Disorder (AUD) is characterized by a compulsion to seek and take alcohol and loss of control in limiting intake. Genetic and environmental factors contribute to the transition from moderate to excessive alcohol consumption. The focus in the lab is investigating the link between exposure to social stressors and increased alcohol use. We use a variety of molecular tools including non-replicating, non-infectious viral vectors and to identify genes and circuits that regulate social-stress induced increases in alcohol consumption.
NIH Guidelines Section(s)	III-E-3
Risk Assessment & Discussion	Personnel working in the laboratory will use appropriate personal protective equipment (PPE), including gloves, lab coats or disposable gowns, head covers, and surgical masks. All work involving biohazardous materials will be conducted within a certified Class II biosafety cabinet (BSL-2 rated) to ensure proper containment and minimize exposure risk.
Training	All institutional trainings required are complete for lab staff listed in the registration: • COI in Research • Laboratory Safety • IBC Compliance • BBP High Risk
EH&S Assessment	The lab was inspected, and no deficiencies were found.
Occupational Health Representative review (if applicable)	N/A
Biosafety Level Assignment	BSL-2 ABSL-1
IACUC status (if applicable)	Application approved
IBC Vote	The Primary Reviewer made a motion to assign the determination of Modifications Required to Secure Approval (MRSA). • Votes: 10/10 for MRSA • COI: None reported Following a duly called vote of the committee, Dr. Maiya's protocol was conditionally approved, pending submission and approval of the requested revisions by the Primary Reviewer.
IBC #8509	**Interactions of KSHV with host innate immune and anti-viral restriction systems**
PI Name	Roy, Arunava
Project Overview	Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) is an oncogenic herpesvirus linked to AIDS-associated malignancies such as Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. The research aims to investigate KSHV's interactions with host innate immune and antiviral restriction factors, with the goal of understanding how the virus establishes latency and evades immune defenses. Findings are expected to inform therapeutic strategies targeting KSHV-related inflammation and cancer. All work will be conducted under BSL-2 conditions in accordance with LSUHSC safety protocols.
NIH Guidelines Section(s)	III-D-3-a III-E-1

	III-F-1 III-F-8 Appx C-II
Risk Assessment & Discussion	Personnel working in the laboratory will use appropriate personal protective equipment (PPE), including gloves, lab coats or disposable gowns, head covers, and surgical masks. All work involving biohazardous materials will be conducted within a certified Class II biosafety cabinet (BSL-2 rated) to ensure proper containment and minimize exposure risk.
Training	All institutional trainings required are complete for lab staff listed in the registration: • COI in Research • Laboratory Safety • IBC Compliance • BBP High Risk
EH&S Assessment	The lab was inspected, and no deficiencies were found.
Occupational Health Representative review (if applicable)	N/A
Biosafety Level Assignment	BSL-2
IACUC status (if applicable)	N/A
IBC Vote	The Primary Reviewer made a motion to assign the determination of Modifications Required to Secure Approval (MRSA) • Votes: 9/10 for MRSA, 1/10 for Defer for Information • COI: None reported Following a duly called vote of the committee, Dr. Roy's protocol was conditionally approved, pending submission and approval of the requested revisions by the Primary Reviewer.
IBC #8853	**Enhancement of HER2-targeted therapy in refractory HER2-positive breast cancer**
PI Name	Liu, Bolin
Project Overview	This study investigates resistance mechanisms in HER2-positive breast cancer, where tumors often become unresponsive to therapies like Herceptin. Researchers found that reduced expression of PPP3CB leads to increased levels of IGF2 and IRS1, contributing to treatment resistance. The project aims to identify the cause of PPP3CB downregulation and test whether inhibiting IGF2 or restoring PPP3CB expression can reverse resistance and enhance the effectiveness of HER2-targeted therapies.
NIH Guidelines Section(s)	III-E-1
Risk Assessment & Discussion	Personnel will utilize appropriate PPE, including gloves, eye protection, lab coats or disposable gowns, and surgical masks. Work will be conducted in both a chemical fume hood and a certified BSL-2 biosafety cabinet, as appropriate. The research involves defective lentiviral vectors and known oncogenes and will be conducted following BSL-2 containment procedures. All biological waste will be collected in designated containers treated with bleach, and laboratory surfaces and equipment will be disinfected with 70% ethanol after each experiment.
Training	All institutional trainings required are complete for lab staff listed in the registration:

	• COI in Research • Laboratory Safety • IBC Compliance • BBP High Risk
EH&S Assessment	The lab was inspected, and no deficiencies were found.
Occupational Health Representative review (if applicable)	N/A
Biosafety Level Assignment	BSL-2 ABSL-2
IACUC status (if applicable)	Application approved
IBC Vote	The Primary Reviewer made a motion to assign the determination of Modifications Required to Secure Approval (MRSA) • Votes: 8/9* for MRSA, 1/9 for Approve • COI: None reported Following a duly called vote of the committee, Dr. Liu's protocol was conditionally approved, pending submission and approval of the requested revisions by the Primary Reviewer. *Guidry left the meeting, quorum remained with 9 committee members
IBC #8873	**Molecular Targets in Prostate Cancer**
PI Name	Koul, Hari
Project Overview	This study aims to address the lack of effective treatments and accurate prognostic tools for metastatic prostate cancer. Researchers propose that Prostate Derived Ets Transcription Factor (PDEF) plays a key role in prostate cancer aggressiveness and may serve as a novel biomarker to distinguish aggressive and metastatic disease from indolent forms. The project includes mechanistic studies to evaluate PDEF's role in metastasis, its potential in patient stratification, and its use in guiding treatment with demethylating agents, with particular attention to addressing disparities between African American and Caucasian men.
NIH Guidelines Section(s)	III-E-1
Risk Assessment & Discussion	Personnel working in the laboratory will use appropriate personal protective equipment (PPE), including gloves, lab coats or disposable gowns, head covers, and surgical masks. All work involving biohazardous materials will be conducted within a certified Class II biosafety cabinet (BSL-2 rated) to ensure proper containment and minimize exposure risk.
Training	All institutional trainings required are complete for lab staff listed in the registration: • COI in Research • Laboratory Safety • IBC Compliance • BBP High Risk
EH&S Assessment	The lab was inspected, and no deficiencies were found.
Occupational Health Representative	N/A

review (if applicable)	
Biosafety Level Assignment	BSL-2 ABSL-2
IACUC status (if applicable)	Application approved
IBC Vote	The Primary Reviewer made a motion to assign the determination of Modifications Required to Secure Approval (MRSA) • Votes: 9/9 • COI: None reported Following a duly called vote of the committee, Dr. Koul's protocol was conditionally approved, pending submission and approval of the requested revisions by the Primary Reviewer.

2:25pm **Adjournment**

The IBC Chair moved to adjourn the meeting at 2:25PM. The next meeting is scheduled for Wednesday, July 9, 2025, via Zoom.